This document is the legal basis for the proposed demerger and the shareholder vote at the extraordinary shareholders meeting. It describes the legal and accounting details of the spin-off and the establishment of medmix. The demerger plan also contains the demerger balance sheet.

In this document, the Board of Directors of Sulzer reports on the rationale and the effects of the demerger for the shareholders of Sulzer as well as on other relevant topics.

In this audit report KPMG, acting as auditor for the demerger, confirms that the planned transaction complies with Swiss Law.